Nature

BRAF — a tumour-agnostic drug target with lineage-specific dependencies

The FDA-approved BRAF inhibitors vemurafenib, dabrafenib and encorafenib selectively inhibit activated BRAF V600E/K/R/D monomers (class I BRAF mutants) in cancer cells, which underlies their clinical ...
ascopubs.org

Clinical Activity of Pertuzumab (rhuMAb 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer: Potential Predictive Relationship With Tumor HER2 Activation Status

DNA-Repair Gene Polymorphisms Predict Favorable Clinical Outcome Among Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Treated With Cisplatin-Based Induction Chemotherapy Median ...
ascopubs.org

Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After ...

Double-Blinded Randomized Study of High-Dose Calcitriol Plus Docetaxel Compared With Placebo Plus Docetaxel in Androgen-Independent Prostate Cancer: A Report From the ASCENT Investigators Pertuzumab ...
GEN

Insights on Melanoma’s Resistance to Vemurafenib Revealed

Spliced variants of BRAF(V600E) lack key exons that encompass RAS-binding domain. Scientists say additional changes to the sequence of BRAF(V600E) that arise in melanoma tumors on repeated exposure to ...